All News

    Lenvima Plus Keytruda With TACE May Improve Liver Cancer Outcomes

    March 10th 2025, 7:00pm

    Article

    For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes.

    On Alcohol Addiction for the Patient With Cancer

    March 10th 2025, 5:00pm

    Article

    As a cancer survivor, I overcame alcohol addiction and urge others to seek support, safe detox and sobriety to improve their treatment and recovery.

    Understanding the Best Practices Associated With CDK4/6 Therapy in Breast Cancer

    March 10th 2025, 4:00pm

    Video

    Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.

    We Have Come a Long Way

    March 10th 2025, 3:00pm

    Article

    CURE magazine's outgoing editor-in-chief, Dr. Debu Tripathy, reflects on 18 years of advances in cancer care, the impact of AI and the evolving future of oncology treatment.

    Gleevec Response in GIST May Be Linked to Mutational Profile

    March 10th 2025, 1:00pm

    Article

    Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing mutation testing for treatment decisions.

    ctDNA May Predict Biliary Tract Cancer Relapse, Recurrence

    March 9th 2025, 2:00pm

    Article

    Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage biliary tract cancer.

    FDA Approves Biosimilars for Cancer-Related Skeletal Events

    March 8th 2025, 7:00pm

    Article

    The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.

    Imfinzi Plus Chemo May Improve Event-Free Survival in Gastric, GEJ Cancers

    March 8th 2025, 3:00pm

    Article

    Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric and gastroesophageal junction cancers.

    177Lu-edotreotide May Delay Progression in Neuroendocrine Tumor Subset

    March 7th 2025, 10:00pm

    Article

    177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

    The Dawn of a New Era in Cancer Treatment

    March 7th 2025, 8:00pm

    Article

    New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and enhancing survivorship care and support for patients.